ProductBrain Intelligence

Should broadening from a single indication (e.g. acute stroke) into additional disease areas move higher on our roadmap because buyers are starting to expect multi-condition clinical AI platforms?

Should we accelerate our AI legal-workflow capabilities now, or double down on adjacencies like billing and matter management where pure-play AI is weaker?

Should we augment our static credit-tier model with per-transaction AI decisioning — and are buyers starting to expect a credit decision tuned to each purchase?

Are commercial banking buyers beginning to expect platforms that orchestrate AI agents end-to-end, rather than software that guides humans through workflow steps?

Are construction buyers about to expect purpose-built AI that reviews documents in days, not weeks — making our generic AI layer a liability?

Should AI-driven operational efficiency become an explicit, measurable story on our roadmap before investors and boards demand it externally?

Should your team maintain deep, differentiated coverage of both SAT and ACT formats independently, or is the architectural cost of hedging across both now diluting the product depth that drives conversion and retention — especially before consolidated-format signals become clear?